anastrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   123 Trials   123 Trials   2738 News 


«12...1112131415161718192021...4142»
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
    Computational drug design of aromatase inhibitors as a treatment for endometriosis (In-Person Room (Virtual Room)) -  Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_3107;    
    Various computational chemistry programs, such as AMBER’s molecular dynamics (MD) and MMPBSA, were then used to assess the binding of each ligand to aromatase. Many of these ligands have shown promise as potential aromatase inhibitor drugs for the treatment of endometriosis.Figure 1: Isoflavanone scaffold
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal:  A Case of Pyloric Stenosis Due to Gastric Metastasis of Breast Cancer (Pubmed Central) -  Jan 26, 2022   
    Systemic chemo-endocrine therapy(EC and anastrozole) was performed, following which her symptoms improved...Thereafter, systemic chemo-endocrine therapy(paclitaxel plus bevacizumab and fulvestrant)was initiated, and her symptoms showed improvement...She was treated using endoscopic biliary stenting, but died 2 months later. Gastric metastasis is reported rarely in 4% of all breast cancers, and GS should be recommended in cases of recurrent abdominal complaints.
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial termination, Trial primary completion date:  Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) -  Jan 21, 2022   
    P2,  N=3, Terminated, 
    In this article, we report a very rare case of recurrence 43 years after surgery. Trial completion date: Nov 2021 --> Jan 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2021 --> Jan 2021; Slow to accrual
  • ||||||||||  camizestrant (AZD9833) / AstraZeneca
    Trial completion date:  SERENA-1: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (clinicaltrials.gov) -  Jan 21, 2022   
    P1,  N=340, Recruiting, 
    Trial completion date: Nov 2021 --> Jan 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2021 --> Jan 2021; Slow to accrual Trial completion date: Sep 2023 --> Dec 2023
  • ||||||||||  bicalutamide / Generic mfg.
    Clinical, Journal:  A Case of Familial Male-Limited Precocious Puberty with a Novel Mutation. (Pubmed Central) -  Jan 12, 2022   
    Because the disorder is so rare, little is known about the long-term effects of treatment; however, studies using bicalutamide and anastrozole have been promising. In this report, we present a case of FMPP with a novel mutation in the LHCGR gene, who has been responding well to therapy using both drugs.
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen
    Trial completion date, Trial primary completion date:  T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (clinicaltrials.gov) -  Jan 12, 2022   
    P1b,  N=25, Recruiting, 
    Whilst objective response rates with anastrozole are low, the clinical benefit rate and good tolerance suggests that aromatase inhibitor therapy may have a role in a subset of patients with metastatic LMS and UCS. Trial completion date: Feb 2022 --> Apr 2023 | Trial primary completion date: Feb 2022 --> Apr 2023
  • ||||||||||  Herceptin (trastuzumab) / Roche, Nerlynx (neratinib) / Puma
    Trial completion date, Trial initiation date, Trial primary completion date:  Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (clinicaltrials.gov) -  Jan 12, 2022   
    P2,  N=48, Not yet recruiting, 
    Trial completion date: Feb 2022 --> Apr 2023 | Trial primary completion date: Feb 2022 --> Apr 2023 Trial completion date: Aug 2022 --> Aug 2024 | Initiation date: Jun 2021 --> Sep 2022 | Trial primary completion date: Jun 2022 --> Aug 2023
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Trial termination, Combination therapy:  Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer (clinicaltrials.gov) -  Jan 11, 2022   
    P2,  N=17, Terminated, 
    Trial completion date: Aug 2022 --> Aug 2024 | Initiation date: Jun 2021 --> Sep 2022 | Trial primary completion date: Jun 2022 --> Aug 2023 Active, not recruiting --> Terminated; lost funding
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, HEOR, Patient reported outcomes, Metastases:  PRECYCLE: Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (clinicaltrials.gov) -  Jan 6, 2022   
    P4,  N=532, Terminated, 
    Trial completion date: Sep 2021 --> Sep 2022 N=960 --> 532 | Trial completion date: Jun 2027 --> Dec 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2027 --> Dec 2021; Due to COVID-19 pandemic, study cannot be finished in planned timeframe.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Clinical, PK/PD data, Journal:  Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients. (Pubmed Central) -  Dec 23, 2021   
    The PK/PD analysis confirmed reversibility of ribociclib effect on ANC; it also suggested that lowering dose of ribociclib would mitigate ANC decrease and neutropenia risk. The popPK and ANC PK/PD analyses support the use of ribociclib in combination with an aromatase inhibitor or fulvestrant in patients with HR+, HER2- advanced or metastatic breast cancer without dose adjustment in subpopulations, and the use of dose interruption/reduction to mitigate potential treatment-emergent neutropenia.
  • ||||||||||  TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
    New trial, Real-world evidence, Real-world, Metastases:  H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI (clinicaltrials.gov) -  Dec 22, 2021   
    P=N/A,  N=40, Recruiting, 
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Enrollment change, Combination therapy, Metastases:  A Study of Abemaciclib in Indian Women With Advanced Breast Cancer (clinicaltrials.gov) -  Dec 21, 2021   
    P4,  N=200, Recruiting, 
    The popPK and ANC PK/PD analyses support the use of ribociclib in combination with an aromatase inhibitor or fulvestrant in patients with HR+, HER2- advanced or metastatic breast cancer without dose adjustment in subpopulations, and the use of dose interruption/reduction to mitigate potential treatment-emergent neutropenia. N=100 --> 200
  • ||||||||||  tamoxifen / Generic mfg.
    Journal:  Endocrine prevention of breast cancer. (Pubmed Central) -  Dec 16, 2021   
    Despite the current infrequent usage, endocrine prevention has the potential to reduce the public health burden of BC significantly. Innovative approaches like finding new agents, alternative dosing and schedule of currently available agents, transdermal medication delivery, increased public and professional awareness, and policymakers' commitments may bring the desired changes.
  • ||||||||||  amcenestrant (SAR439859) / Sanofi
    Trial completion date, Trial primary completion date, Monotherapy, Metastases:  AMEERA-3: Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (clinicaltrials.gov) -  Dec 15, 2021   
    P2,  N=372, Recruiting, 
    Innovative approaches like finding new agents, alternative dosing and schedule of currently available agents, transdermal medication delivery, increased public and professional awareness, and policymakers' commitments may bring the desired changes. Trial completion date: Jul 2025 --> Nov 2025 | Trial primary completion date: Nov 2021 --> Feb 2022
  • ||||||||||  anastrozole / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  PHANTOM: Pulmonary Hypertension and Anastrozole Trial (clinicaltrials.gov) -  Dec 6, 2021   
    P2,  N=84, Active, not recruiting, 
    Trial completion date: Jul 2025 --> Nov 2025 | Trial primary completion date: Nov 2021 --> Feb 2022 Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022 | Recruiting --> Active, not recruiting
  • ||||||||||  tamoxifen / Generic mfg.
    Clinical, Journal, Adverse events:  Visualizing adverse events in clinical trials using correspondence analysis with R-package visae. (Pubmed Central) -  Nov 25, 2021   
    Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022 | Recruiting --> Active, not recruiting CA with contribution biplot is an effective tool that can be used to summarize AE data in a two-dimensional display while minimizing the loss of information and interpretation.
  • ||||||||||  anastrozole / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Journal:  Maxillary bone metastasis, as an early sign of breast cancer; an unusual & rare site of metastasis from the common cancer. (Pubmed Central) -  Nov 21, 2021   
    A high index of clinical thought of metastatic cancer to maxilla is necessary when evaluating patients who complain of maxillary pain and swelling without a history of pain or swelling in the head and neck & non-head and neck region. To the best of our knowledge, this is the first reported case of a metastatic isolated solitary maxillary bone metastasis presenting as an early sign of breast cancer.
  • ||||||||||  paclitaxel / Generic mfg.
    Metastatic Invasive Lobular Carcinoma Mimicking Plasmacytoid Urothelial Carcinoma of the Bladder () -  Nov 20, 2021 - Abstract #PROSCABLADDR2021PROSCA_BLADDR_44;    
    She underwent appropriate neoadjuvant chemotherapy and anastrozole...Retrograde decompression with a JJ stent was performed and subsequent palliative paclitaxel and then Palbociclib were trailed...The need for clear communication between surgical and pathology teams is also highlighted for accurate reporting. Positive staining of mammaglobin and hormone receptors in a bladder tumour with initial appearance of plasmacytoid urothelial carcinoma should raise suspicion for metastatic lobular carcinoma of the breast.
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
    Enrollment open, Trial initiation date, Metastases:  SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. (clinicaltrials.gov) -  Nov 11, 2021   
    P2,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2021 --> Aug 2021
  • ||||||||||  tamoxifen / Generic mfg.
    Clinical, Clinical data, Review, Journal:  Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic review. (Pubmed Central) -  Nov 7, 2021   
    The results of our systematic review highlight a need for further research exploring the optimal endocrine therapies for obese women. There is insufficient evidence at present to recommend tailoring adjuvant endocrine therapy with use of specific AIs or for dosing modifications of AIs in this patient population.
  • ||||||||||  anastrozole / Generic mfg.
    Clinical, Journal:  Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density. (Pubmed Central) -  Nov 7, 2021   
    According to the presence of hormonal receptors, HER2 and Ki67, seventeen had positive hormonal receptors and received anastrozole (AI group), and seventeen were triple-negative receptors (non-AI group), previously treated with chemotherapy...AI is associated with alterations in bone density and microarchitecture of both the cortical and trabecular compartments. These findings explain the overall increase in fracture risk in this specific population.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  Endocrine Response in Women With Invasive Lobular Breast Cancer (clinicaltrials.gov) -  Nov 1, 2021   
    P2,  N=170, Recruiting, 
    These results corroborate the lack of cross-resistance between AIs verified in the clinic, excluding autophagy as a mechanism of resistance to Ana or Let and supporting the ongoing clinical trials combining BYL-719 with AIs. Trial completion date: Feb 2023 --> Mar 2022 | Trial primary completion date: Feb 2023 --> Mar 2022
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  CardioVOLT: Cardiovascular Outcomes of Low Testosterone (clinicaltrials.gov) -  Oct 27, 2021   
    P=N/A,  N=379, Recruiting, 
    1993;365:652-654. Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
  • ||||||||||  limantrafin (CB-103) / Cellestia Biotech
    Enrollment closed:  CAILA: CB-103 Plus NSAI In Luminal Advanced Breast Cancer (clinicaltrials.gov) -  Oct 26, 2021   
    P2,  N=80, Active, not recruiting, 
    Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Sep 2021 --> Sep 2022 Recruiting --> Active, not recruiting